• All
  • Articles
  • Squawks
  • Trade views
  • Must reads
  • Videos
  • Calendar
Write a Squawk
No posts
  • Article / 28 May 2018 at 8:22 GMT

    Genmab shares down 20% – our take

    Head of Equity Strategy / Saxo Bank
    Genmab shares down 20% – our take
    Europe’s largest biotechnology company Genmab is down 20% today after opening 25% lower as one of its key studies on cancer treatments is stopped. This is obviously a big blow to their efforts in the combo trials (mixing drugs for cancer treatments) and investors were hoping for a blockbuster potential in this study.
    Read the article
  • 2y
    yakcay yakcay
    Hi Kim. What is your current view for Genmab now that it has approached the 1300 DKK you mentioned above? Should we expect a dive from here?...
    Kim Cramer Larsson Kim Cramer Larsson
    well, Genmab could still try to push a bit higher maybe to 1321-1350 before resuming the down trend.
    Currently however, there is not a signal for a...
  • Squawk / 19 May 2014 at 18:12 GMT
    Senior Equity Trader / Saxo Bank
    GlaxoSmithKline and Genmab did not meet primary endpoint with Ofatumumab and are unlikely to move forward with filing
    Read the Squawk